IDH2 and cancer: Consistent with the cancer genomics data analysis (Figure 2B), SRSF2 mutations were enriched in the DNMT3A R882 mutant group compared to the non-R882 mutant group (14.5% vs. 4.8%, p=.03), and mutations of IDH2 and BCOR also show a trend of enrichment in the DNMT3A R882 mutant group (14.5% vs. 4.8%, p=.05 for IDH2, 17.7% vs. 9.6%, p=.06 for BCOR) in comparison to the non-R882 group (Figure 3).